1. Scrip
  2. >>Focus On Asia
  3. >>India

Management team appointments at Biological E

 
• By Zoë Dann

Biological E (India), a manufacturer of vaccines, biologics and pharmaceutical products, has made three appointments to its management team: Dr Martin Reers is named senior vice-president of technical operations, having most recently served as vice-president of technology development global, manufacturing sciences at Novartis/Chiron Vaccines; Dr Gopalam Somasekhar joins as senior vice-president of development – he was previously associate director at Wyeth Vaccines; and Dr Krish Venkat is appointed senior vice-president of quality, having previously worked as consultant to US biotech and pharmaceutical companies on quality and regulatory issues, and vaccine development, as a principal at Anven Research.

Biological E (India), a manufacturer of vaccines, biologics and pharmaceutical products, has made three appointments to its management team: Dr Martin Reers is named senior vice-president of technical operations, having most recently served as vice-president of technology development global, manufacturing sciences at Novartis/Chiron Vaccines; Dr Gopalam Somasekhar joins as senior vice-president of development – he was previously associate director at Wyeth Vaccines; and Dr Krish Venkat is appointed senior vice-president of quality, having previously worked as consultant to US biotech and pharmaceutical companies on quality and regulatory issues, and vaccine development, as a principal at Anven Research.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Chinese Biotech VC/PE Fundings Rise But Still Modest

 
• By Dexter Jie Yan

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.